Share on LinkedInShare on LinkedIn

ARTICLE · 25 JULY 2013

The Process Is An Essential Element Of A Product-By-Process Claim

Sim & McBurney / Sim Lowman Ashton & McKay LLP
Explore more from Sim & McBurney / Sim Lowman Ashton & McKay LLP

Bayer attempted to broaden the scope of a product-by-process claim by arguing that the process recited in the claim was a non-essential feature and should not be considered as part of the claim.

CanadaIntellectual Property
Erica Lowthers
Erica Lowthers

Bayer Inc. v. Cobalt Pharmaceuticals Company 2013 FC 573 (O'Reilly)

Summary – Bayer attempted to broaden the scope of a product-by-process claim by arguing that the process recited in the claim was a non-essential feature and should not be considered as part of the claim. The Court disagreed and found the process steps essential and not infringed by Cobalt, who wished to produce the same product through a different method of manufacture.

Analysis – Bayer holds Canadian Patent No. 2,261,137, directed to processes for producing drospirenone (an oral contraceptive marketed as YasminTM) and drospirenone produced according to these processes. As this was a decision under the Patented Medicines (Notice of Compliance) (PM(NOC)) Regulations, the process claims were not eligible to be asserted. Furthermore, Cobalt indicated that the patented process would not be used. Therefore, only product claim 13 was at issue. Claim 13 is specifically directed to purified

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from